Regenerative Medical Technology (RMTG) Total Liabilities (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Total Liabilities of $40.6 million for Q1 2026, up 26.59% year-over-year from $32.1 million in Q1 2025, and up 3.56% quarter-over-quarter from $39.2 million in Q4 2025.
Regenerative Medical Technology (RMTG) Total Liabilities (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Total Liabilities history runs 10 years deep, the most recent figure standing at $40.6 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 26.59% year-over-year to $40.6 million; the TTM figure through Mar 2026 stood at $40.6 million (up 26.59% YoY), while the FY2025 annual figure was $39.2 million, up 25.84% from the prior year.
- Total Liabilities for Q1 2026 stood at $40.6 million, up from $39.2 million in the prior quarter.
- The five-year high for Total Liabilities was $40.6 million in Q1 2026, with the low at $17.1 million in Q1 2022.
- The 5-year median for Total Liabilities is $26.8 million (2024), against an average of $27.4 million.
- Peak annual rise in Total Liabilities reached 139.18% in 2022, while the deepest fall reached 14.8% in 2022.
- Regenerative Medical Technology's Total Liabilities stood at $20.1 million in 2022, then climbed by 22.99% to $24.7 million in 2023, then increased by 26.36% to $31.2 million in 2024, then increased by 25.84% to $39.2 million in 2025, then climbed by 3.56% to $40.6 million in 2026.
- Business Quant data shows RMTG's Total Liabilities at $40.6 million in Q1 2026, $39.2 million in Q4 2025, and $34.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Regenerative Medical Technology | 961,772.49 | -99,675.51 | 1.77 Mn | 40.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.63 Mn |
| Dec 31, 2025 | 39.23 Mn |
| Sep 30, 2025 | 34.57 Mn |
| Jun 30, 2025 | 33.51 Mn |
| Mar 31, 2025 | 32.10 Mn |
| Dec 31, 2024 | 31.18 Mn |
| Sep 30, 2024 | 29.95 Mn |
| Jun 30, 2024 | 28.88 Mn |
| Mar 31, 2024 | 26.84 Mn |
| Dec 31, 2023 | 24.67 Mn |
| Sep 30, 2023 | 24.85 Mn |
| Jun 30, 2023 | 23.22 Mn |
| Mar 31, 2023 | 21.72 Mn |
| Dec 31, 2022 | 20.06 Mn |
| Sep 30, 2022 | 19.23 Mn |
| Jun 30, 2022 | 18.03 Mn |
| Mar 31, 2022 | 17.13 Mn |
| Dec 31, 2021 | 16.06 Mn |
| Sep 30, 2021 | 22.57 Mn |
| Jun 30, 2021 | 7.54 Mn |